CA2972076A1 - Combination of raf inhibitors and aurora kinase inhibitors - Google Patents

Combination of raf inhibitors and aurora kinase inhibitors Download PDF

Info

Publication number
CA2972076A1
CA2972076A1 CA2972076A CA2972076A CA2972076A1 CA 2972076 A1 CA2972076 A1 CA 2972076A1 CA 2972076 A CA2972076 A CA 2972076A CA 2972076 A CA2972076 A CA 2972076A CA 2972076 A1 CA2972076 A1 CA 2972076A1
Authority
CA
Canada
Prior art keywords
cancer
raf
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2972076A
Other languages
English (en)
French (fr)
Inventor
Viviana BOZON
Katherine M. Galvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA2972076A1 publication Critical patent/CA2972076A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2972076A 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors Abandoned CA2972076A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
PCT/US2015/067459 WO2016106357A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2972076A1 true CA2972076A1 (en) 2016-06-30

Family

ID=56151529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2972076A Abandoned CA2972076A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors

Country Status (6)

Country Link
US (1) US20180263979A1 (enExample)
EP (1) EP3236948A4 (enExample)
JP (1) JP2018502089A (enExample)
CN (1) CN107205933A (enExample)
CA (1) CA2972076A1 (enExample)
WO (1) WO2016106357A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7282674B2 (ja) 2016-10-28 2023-05-29 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤及びオーロラキナーゼ阻害剤を含む医薬品組み合わせならびにその使用方法
JP7291399B2 (ja) * 2017-05-03 2023-06-15 ティン セラピューティクス エルエルシー 難聴の予防および治療のための組成物および方法
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523940A (ja) * 1999-05-11 2003-08-12 オーソ−マクネイル ファーマシューティカル インコーポレイテッド エリスロポエチン投与の薬物速度論的および薬力学的モデリング
EP1656146A4 (en) * 2003-08-15 2009-04-15 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
CN101056632B (zh) * 2004-11-09 2011-12-07 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP2830664A1 (en) * 2012-03-30 2015-02-04 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP3392348A3 (en) * 2014-06-16 2018-11-21 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment

Also Published As

Publication number Publication date
EP3236948A1 (en) 2017-11-01
JP2018502089A (ja) 2018-01-25
US20180263979A1 (en) 2018-09-20
CN107205933A (zh) 2017-09-26
WO2016106357A8 (en) 2017-06-01
EP3236948A4 (en) 2018-10-03
WO2016106357A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
JP2021156893A (ja) Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
US11007184B2 (en) Cancer treatments using combinations of type 2 MEK and ERK inhibitors
JP2013543008A (ja) Ｂｒａｆ阻害剤による治療方法
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
EP3889254A1 (en) A mek1 mutation conferring resistance to raf and mek inhibitors
CN104968347A (zh) 马赛替尼用于治疗使用预测因素鉴别的患者亚群的癌症的用途
EP3661924A1 (en) Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia
WO2013188355A1 (en) Cdk inhibitor for treating refractory chronic lymphocytic leukemia
JP6549147B2 (ja) Ｎｒａｓ変異癌の処置における使用のためのｅｇｆｒ阻害剤とｍｅｋ阻害剤の組合せ
US20200316067A1 (en) Combination of raf inhibitors and taxanes
US20230121116A1 (en) Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions
EP4118237A1 (en) Methods of treating her2 mutant cancers with tucatinib
GB2488028A (en) mTOR mutants as biomarkers for mTOR inhibitor treatment
MX2014006186A (es) Capacidad de respuesta a los inhibidores de la angiogenesis.
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
Ohno Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors
WO2021255518A1 (en) Compositions and methods for treating acute myeloid leukemia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220314